Client Care







Products Range

New product:

Ag Respi-Strip

BL-RED Range

Resist Range










Immunochromatographic Range

Pathogens detection

40/41 Adenovirus


Clostridium difficile

Cryptosporidium & Giardia

Rotavirus & 40/41 Adenovirus


Helicobacter pylori

Influenza A & B viruses


Respiratory Adenovirus

Rotavirus & Adenovirus


Respiratory Syncytial Virus (RSV)

Streptococcus (group A)

Trypanosoma brucei gambiense (HAT)

Quatro-VeT (Veterinary)

Molecular Range

Pseudomonas aeruginosa

Scientific partners



PARADIS (Biowin)

AquaVir (FP7)

Euroleish (H2020-MSCA-ITN)

ebolaMoDRAD (IMI-2)


Products  >  Human-Field  >  Human African Trypanosomiasis  >  Sciences

• A Phase III Diagnostic Accuracy Study of a Rapid Diagnostic Test for Diagnosis of Second-Stage Human African Trypanosomiasis in the Democratic Republic of the Congo.

Boelaert M, Mukendi D, Bottieau E, Kalo Lilo JR, Verdonck K, Minikulu L, Barbé B, Gillet P, Yansouni CP, Chappuis F, Lutumba P.

EBioMedicine. 2018 Jan;27:11-17. doi: 10.1016/j.ebiom.2017.10.032. Epub 2017 Dec 6

OBJECTIVES: To estimate the diagnostic accuracy of HAT Sero K-SeT for the field diagnosis of second-stage human African trypanosomiasis (HAT).
DESIGN: A phase III diagnostic accuracy design. Consecutive patients with symptoms clinically suggestive of HAT were prospectively enrolled. We compared results of the index test HAT Sero K-SeT with those of a composite reference standard: demonstration of trypanosomes in cerebrospinal fluid (CSF), or trypanosomes detected in any other body fluid AND white blood cell count in CSF >5/μl.
SETTING: Rural hospital in the Democratic Republic of the Congo.
PARTICIPANTS: All patients above five years old presenting at Mosango hospital with a neurological problem of recent onset at the exclusion of trauma.
MAIN OUTCOME MEASURES: Sensitivity and specificity of HAT Sero K-SeT test.
RESULTS: The sensitivity of the HAT Sero K-SeT was 8/8 or 100.0% (95% confidence interval: 67.6 to 100.0%) and the specificity was 258/266 or 97.0% (94.2% to 98.5%).
CONCLUSION: The high sensitivity of the HAT Sero K-SeT is in line with previously published estimates, though the sample of HAT cases in this study was small. The specificity estimate was very high and precise. This test, when negative, allows the clinician to rule out HAT in a clinical suspect in a hospital setting in this endemic region.


• Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness cased by Trypanosoma brucei gambiense: a case-control study.

P. Büscher, P. Mertens, T. Leclipteux, Q. Gilleman, D. Jacquet, D. Mumba-Ngoyi, P. Pati Pyana, M. Boelart, V. Lejon

Lancet Glob Health. 2014 Jun;2(6):e359-63. doi: 10.1016/S2214-109X(14)70203-7. Epub 2014 May 9.

 Rapid diagnostic test for serodiagnosis of sleeping sickness



• Preliminary evaluation of the diagnostic performance of the HAT Sero K-SeT rapid diagnostic test in Guinea. 

O. Camara, M. Camara, H. Sakande, M. Leno, E. Dama, Q. Gilleman, P. Büscher, B. Bucheton, V. Jamonneau and V. Lejon.

ISCTRC 2013 Khartoum

 Evaluation of HAT Sero K-SeT Rapid Diagnostic Test



• Rapid Diagnostic Test for Sleeping Sickness.

P. Büscher, Q. Gilleman and V. Lejon

New England Journal of Medecine 14: 1069-70, 2013



• Rapid diagnostic test for neurological infections in central Africa.

C.P. Yansouni, E. Bottieau, P. Lutumba, A.S. Winkler, L. Lynen, P. Büscher, J. Jacobs, P. Gillet, V. Lejon, E. Alirol, K. Polman, J. Utzinger, M.A. Miles, R.W. Peeling, J-J. Muyembe, F. Chappuis and M. Boelart

Lancet Infectious Diseases 13: 546-58, 2013


Infections are a leading cause of life-threatening neuropathology worldwide. In central African countries affected by endemic diseases such as human African trypanosomiasis, tuberculosis, HIV/AIDS, and schistosomiasis, delayed diagnosis and treatment often lead to avoidable death or severe sequelae. Confirmatory microbiological and parasitological tests are essential because clinical features of most neurological infections are not specific, brain imaging is seldom feasible, and treatment regimens are often prolonged or toxic. Recognition of this diagnostic bottleneck has yielded major investment in application of advances in biotechnology to clinical microbiology in the past decade. We review the neurological pathogens for which rapid diagnostic tests are most urgently needed in central Africa, detail the state of development of putative rapid diagnostic tests for each, and describe key technical and operational challenges to their development and implementation. Promising field-suitable rapid diagnostic tests exist for the diagnosis of human African trypanosomiasis and cryptococcal meningoencephalitis. For other infections-eg, syphilis and schistosomiasis-highly accurate field-validated rapid diagnostic tests are available, but their role in diagnosis of disease with neurological involvement is still unclear. For others-eg, tuberculosis-advances in research have not yet yielded validated tests for diagnosis of neurological disease.



• Sleeping sickness elimination: are we dreaming?

P. Büscher, Q. Gilleman and P. Mertens

CLI, pp22-24, 2013


Recent sleeping sickness epidemics killed over 400,000 people in less than 20 sub-Saharan African countries. Serological screening of populations at risk and treatment of confirmed patients have drastically reduced the annually reported cases. Elimination seems feasible but only with new control tools and strategies adapted to the new epidemiological situation.



• Rapid Development of rapid diagnostic tests for surra and sleeping sickness based on recombinant antigens expressed in Pichia pastoris.

S. Rogé, M. Meul, Y. Guisez, Q. Gilleman, T. Simon and P. Büscher

Institute of Tropical Medecine, November, 2012

 Rapid Development of rapid diagnostic test for surra and Sleeping Sickness



• Development of a rapid Diagnostic Test for detection of sleeping sickness.

Q. Gilleman, P. Mertens and P. Bûscher

Poster Science For Business - BioWin Day, 2012

 Devolpment of a Rapid Diagnostic Test for detection of sleeping sickness

Home   -   Site Map   -   Privacy Policy   -   Contact   -   FAQ                   All rights reserved CorisBioconcept SPRL 1996-2012©                 

Web traffic Optimisation

Design, Programming & hosting
Impact communication